Milrinone

Catalog No.S2484 Batch:S248401

Print

Technical Data

Formula

  C12H9N3O
Molecular Weight 211.22 CAS No. 78415-72-2
Solubility (25°C)* In vitro DMSO 42 mg/mL (198.84 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Milrinone (Win 47203,Primacor) is a phosphodiesterase 3 (PDE3) inhibitor, used to increase the heart's contractility.
Targets
ATPase [1] PDE3 [7] PDE2 [7]
2.1 μM 5.2 μM
In vitro

Milrinone causes a concentration-dependent increase in the cAMP level in rabbit and human platelets with similar potency. Milrinone inhibits human platelet aggregation with a median inhibitory concentration (IC50) of 2 mM.Milrinone concentration-dependently increases left ventricular developed pressure (LVDP) and contractility. Milrinone concentration-dependently increases cAMP in rabbit coronary smooth muscle cells. [1] Milrinone increases intracellular cyclic adenosine monophosphate by inhibiting Type III phosphodiesterase. [2] Milrinone is a potent (IC50 = 0.16-0.90 mM) and selective (100 times peak III relative to peak I) peak III inhibitor. Milrinone significant increases in cAMP content accompany significant vasorelaxation. [3]
In vivo

Milrinone inhibits PDE4 in addition to PDE3 activity in the rabbit heart.Milrinone (>10 microM) causes greater elevations in intracellular cAMP and calcium than cilostazol. [4] Milrinone causes similar increases in heart rate, cardiac output, and left ventricular +dP/dt and decreases in end-diastolic pressure and systemic vascular resistance in anaesthetized dogs. [5] Milrinone leads to significant increases in right ventricular function as well as significant improvements in pulmonary vascular resistance, pulmonary blood flow, and left ventricular filling in mongrel dogs underwent pulmonary artery catheterization. [6]

Protocol (from reference)

Customer Product Validation

, , Mol Pharm, 2017, doi: 10.1021/acs.molpharmaceut.7b00360

Selleck's Milrinone has been cited by 3 publications

The function of Nucleoporin 37 on mouse oocyte maturation and preimplantation embryo development [ J Assist Reprod Genet, 2022, 10.1007/s10815-021-02330-x] PubMed: 35022896
Glucocorticoid-induced CREB activation and myostatin expression in C2C12 myotubes involves phosphodiesterase-3/4 signaling [Xie Y, et al. Biochem Biophys Res Commun, 2018, 503(3):1409-1414] PubMed: 30025893
A novel milrinone nanoformulation for use in cardiovascular diseases: preparation and in vitro characterization. [Lomis N, et al. Mol Pharm, 2017, 10.1021/acs.molpharmaceut.7b00360] PubMed: 28837343

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.